Last reviewed · How we verify
18F-FDG
18F-FDG is a Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved. Also known as: 18F-fluorodeoxyglucose, fluorodeoxyglucose-F-18, [18F]F-FDG, Fludeoxyglucose.
At a glance
| Generic name | 18F-FDG |
|---|---|
| Also known as | 18F-fluorodeoxyglucose, fluorodeoxyglucose-F-18, [18F]F-FDG, Fludeoxyglucose, fdg |
| Sponsor | Peking University First Hospital |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin (PHASE1)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (PHASE1,PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1,PHASE2)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1,PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-FDG CI brief — competitive landscape report
- 18F-FDG updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI
Frequently asked questions about 18F-FDG
What is 18F-FDG?
18F-FDG is a Small molecule drug developed by Peking University First Hospital.
Who makes 18F-FDG?
18F-FDG is developed and marketed by Peking University First Hospital (see full Peking University First Hospital pipeline at /company/peking-university-first-hospital).
Is 18F-FDG also known as anything else?
18F-FDG is also known as 18F-fluorodeoxyglucose, fluorodeoxyglucose-F-18, [18F]F-FDG, Fludeoxyglucose, fdg.
What development phase is 18F-FDG in?
18F-FDG is FDA-approved (marketed).
Related
- Manufacturer: Peking University First Hospital — full pipeline
- Therapeutic area: All drugs in Metabolic
- Also known as: 18F-fluorodeoxyglucose, fluorodeoxyglucose-F-18, [18F]F-FDG, Fludeoxyglucose, fdg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing